Key result
Sarcoma carries a ~8% overall VTE incidence, predicted by metastatic disease and chemotherapy.
Why the study?
Little has been published about the association of venous thromboembolism and sarcoma, motivating identification of clinical features in sarcoma patients with VTE.
What are the predictive factors for venous thromboembolism in patients with sarcoma?
Case-Control
No
What are the predictive factors for venous thromboembolism in patients with sarcoma?
VTE occurs in approximately 7.9% of sarcoma patients, particularly those with metastatic disease or receiving chemotherapy, highlighting the need for appropriate thromboprophylaxis.
May inform VTE risk stratification in metastatic sarcoma on chemotherapy; hypothesis-generating pending prospective validation.
Background Little has been published about the association of venous thromboembolism (VTE) and sarcoma. In this study, we sought to identify clinical features of patients with sarcoma presenting at least one VTE episode. Methods Our study was a retrospective case–control study of a single-institution database with univariate and multivariate analysis using chi-square and Student's t test. A p value less than .05 was considered significant. Results The overall incidence of VTE in patients with sarcoma was 7.9%. Predictive factors identified by multivariate analysis were metastatic disease and administration of chemotherapy. It was not statistically possible to correlate the risk of VTE with specific sarcoma subtypes, but observations suggested malignant peripheral nerve sheath tumor, osteosarcoma, and liposarcoma as having the highest propension. Conclusion VTE is not infrequent in patients with sarcoma. Adoption of common guidelines for cancer-associated thrombosis is recommended.
No takes yet. Share an insight, caveat, or question.
Alcindor et al. (2018) conducted a case-control in Sarcoma. Metastatic disease and chemotherapy was evaluated on Venous thromboembolism (VTE). The overall incidence of venous thromboembolism in patients with sarcoma was 7.9%, with metastatic disease and chemotherapy administration identified as predictive factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: